Cell Reports MethodsMicrobiologyPeer-reviewed journal article
A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
K. Matsuda, S. Islam, T. Takada, K. Tsuchiya, B. J. Y. Tan, S.-i. Hattori, H. Katsuya, K. Kitagawa, K. S. Kim, M. Matsuo, N. S. Delino, H. Gatanaga, K. Yoshimura, S. Matsushita, H. Mitsuya, S. Iwami, Y. Satou, K. Maeda
Abstract
Persistence of HIV-1 latent reservoir cells during antiretroviral therapy is a major obstacle for curing HIV-1. Latency-reversing agents (LRAs) are under development to reactivate and eradicate latently infected cells; however, there are few useful models for evaluating LRA activity in vitro. Here, we established a long-term cell culture system harboring thousands of different HIV-1-infected cell clones with a wide distribution of HIV-1 provirus similar to that observed in vivo. A combination of an LRA and antiretroviral therapy (ART) significantly reduced viral rebound upon treatment interruption. Experimental investigation and mathematical modeling demonstrated that addition of LRA to ART induced latency-reversing effect and contributed to the eradication of replication competent HIV-1. The widely distributed intact provirus elimination (WIPE) assay will be useful for optimizing therapeutics against HIV-1 latency and investigating mechanistic insights into the clonal selection of heterogeneous HIV-1-infected cells.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A truncated HIV Tat demonstrates potent and specific latency reversal activity
E. Van Gulck, M. Pardons, … D. Boden·bioRxiv·Mar 2, 2023
- Identification of a novel small molecule facilitating HIV elimination by the "Shock-and-Kill" approach
Yuichiro Hara, Haruki Kitamura, … Hiroaki Takeuchi·Journal of Medical VirologyPeer-reviewed·Aug 31, 2026
- Reduction of the HIV-1 reservoir in T cells from persons with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells ex vivo
M. A. Checkley Luttge, B. G. LUTTGE, … J. Karn·bioRxiv·Sep 5, 2022
- Vpr shapes the proviral landscape and polyclonal HIV-1 reactivation patterns in cultured cells
E. Atindaana, S. Emery, … A. Telesnitsky·bioRxiv·Oct 8, 2021
- Identification of Celastrol as a novel HIV-1 Latency Reversal Agent by an Image-Based Screen
A. P. Rice, H. Liu, … B. Nikolai·bioRxiv·Dec 17, 2020
- A transient heritable memory regulates HIV reactivation from latency